Table 1 Demographic, Clinical, and Neuropsychological Data at Baseline
Variables | BC group (n = 17) | HC group(n = 19) | P value |
|---|---|---|---|
Age (years) | |||
 median ± (IQRs) | 46 (40–50) | 47 (36–52) | 0.505c |
Education levels (years) | |||
 median ± (IQRs) | 12 (9–14) | 15 (11–16) | 0.065c |
Premenopause, n (%) | 11 (64.7) | 11 (57.9) | 0.896b |
Menopause, n (%) | 6 (35.3) | 8 (42.1) | 0.734b |
Breast cancer stage, n (%) | |||
 I | 4 (23.5) | NA | NA |
 II | 7 (41.2) | NA | NA |
 III | 6 (35.3) | NA | NA |
Chemotherapy regimen stage (I-III) | Â | NA | NA |
 Postoperative chemotherapy, (I-III) |  |  | |
 AC-T (eight cycles), n (%) | 11 (64.7) | NA | NA |
 Neoadjuvant chemotherapy, (I-III) |  |  | |
 TEC (six cycles), n (%) | 5 (29.4) | NA | NA |
 AC-T (eight cycles), (IIB) | 1 (5.9) |  |  |
Clinical data, median ± (IQRs) | |||
 SAS (score) | 29.0 (27.0–31.75) | 25.0 (22.8–26.0) | 0.012c |
 SDS (score) | 27.5 (24.5–32.0) | 23.0 (22.0–27.0) | 0.002c |
 E2 (pmol/L) | 265.0 (112.3–391.8) | 83.0 (42.0–199.0) | 0.220c |
 FSH (IU/L) | 6.9 (3.9–40.1) | 26.8 (8.1–80.3) | 0.021a |
 LH (IU/L) | 7.3 (2.2–25.4) | 21.6 (8.3–40.6) | 0.501c |
 Hemoglobin(g/L) | 124.0 (110.0–134.0) | 131.0 (125.0–136.0) | 0.334c |
 Total cholesterol (mmol/L) | 4.9 (4.3–5.7) | 5.2 (4.5–5.7) | 0.037c |
 Triglycerides (mmol/L) | 1.5 (0.9–3.0) | 0.8 (0.6–1.7) | 0.030c |
 Fasting glucose (mmol/L) | 5.2 (4.7–7.2) | 4.9 (4.6–5.2) | 0.005a |
Cognitive performance, median ± (IQRs) | |||
 MMSE (score) | 28.0 (27.0–29.5) | 29.0 (28.0–30.0) | 0.061c |
 DST (score) | 49.5 (34.0–61.8) | 62.0 (45.0–69.0) | 0.408c |
 LTT (sec) | 59.8 (46.1–83.2) | 32.3 (24.2–38.1) | 0.429c |
 SDT (sec) | 37.5 (33.3–42.3) | 30.7 (27.1–34.5) | 0.050a |
 WDT (score) | 24.0 (22.0–27.0) | 27.0 (24.5–29.3) | 0.010a |
 Stroop-C (sec) | 15.3 (13.5–18.4) | 13.8 (9.9–15.8) | 0.005a |
 Stroop-W (sec) | 22.0 (18.5–26.1) | 16.0 (13.5–18.5) | < 0.001c |
 Stroop-I (sec) | 31.5 (24.9–33.0) | 24.3 (19.2–28.4) | 0.003c |